Hospital Events

Developing An Integrative Approach to Metastatic Prostate Cancer: Making it Personal to Improve Clinical Outcomes

Developing An Integrative Approach to Metastatic Prostate Cancer:  Making it Personal to Improve Clinical Outcomes
The treatment arsenal for the care of castrate resistant prostate cancer (CRPC) patients has recently expanded to include not only chemotherapy, but also growth factor receptor inhibition, secondary hormonal manipulations, immunotherapy, and most recently nuclear therapy.

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

As participants in this continuing medical education activity, clinicians and other healthcare providers who treat and/or care for patients with multiple myeloma (MM) will be presented with information on strategies for induction and maintenance in transplant eligible patients. 

Current Advances in Management of T-cell Lymphoma: Assessing Current Research, Developing Therapeutic Approaches and the Emergence of Individualizing Treatment

Current Advances in Management of T-cell Lymphoma: Assessing Current Research, Developing Therapeutic Approaches and the Emergence of Individualizing Treatment

T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders that account for 15% of all non-Hodgkin lymphomas (NHLs). The majority of these are peripheral T-cell lymphomas (PTCL). T-cell lymphomas are highly variable in their clinical presentation and prognosis. Research over the past few decades has revealed that these malignancies are biologically distinct with unique molecular, pathologic, and clinical features. This understanding has led to greater classification of T-cell lymphomas into separate subtypes. The identification of these malignancies as distinct entities is improving outcomes for patients with PTCL by enabling greater individualization of therapy and identifying new therapeutic targets.

Evolving Therapeutic Approaches and Shifting Paradigms in the Treatment of Multiple Myeloma

Evolving Therapeutic Approaches and Shifting Paradigms in the Treatment of Multiple Myeloma

This activity brings leading myeloma experts together to discuss some of the most important issues in myeloma today, including current and future practice for patients with smoldering myeloma, the development of novel targeted therapies; evolving clinical paradigms on timing of HDT-ASCT and continuous /maintenance therapy; the evolution of treatment strategies to overcome acquired resistance to therapy including new combination therapies and new classes of therapeutics never before used in multiple myeloma.

Insights to Optimizing Therapeutic Approaches for T-cell lymphomas

Insights to Optimizing Therapeutic Approaches for T-cell lymphomas

T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders that account for 15% of all non-Hodgkin lymphomas (NHLs). The majority of these are peripheral T-cell lymphomas (PTCL). T-cell lymphomas are highly variable in their clinical presentation and prognosis. Research over the past few decades has revealed that these malignancies are biologically distinct with unique molecular, pathologic, and clinical features. This understanding has led to greater classification of T-cell lymphomas into separate subtypes. The identification of these malignancies as distinct entities is improving outcomes for patients with PTCL by enabling greater individualization of therapy and identifying new therapeutic targets.

Update on Follicular Lymphoma: Contemporary Treatment Strategies and Optimal Sequencing

Update on Follicular Lymphoma: Contemporary Treatment Strategies and Optimal Sequencing

This live interactive program will focus on current patient management practices in follicular lymphoma, a review of FDA approved agents, current clinical trials and new prognostic information. A discussion on where radioimmunotherarpy may fit into the treatment strategy will also be included.